Thymic Carcinoma
39
6
10
13
Key Insights
Highlights
Success Rate
65% trial completion
Published Results
11 trials with published results (28%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 47/100
17.9%
7 terminated out of 39 trials
65.0%
-21.5% vs benchmark
3%
1 trials in Phase 3/4
85%
11 of 13 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 13 completed trials
Clinical Trials (39)
Postoperative Adjuvant Chemotherapy for Thymic Cancer (FUSCC-Thymic 3)
A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy
Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer
Neoadjuvant Adebrelimab Plus CRT for Locally Advanced Thymic Carcinoma
Electrocautery Resection Combined With HITHOC for Thymic Epithelial Tumors With Pleural Metastasis
A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors
Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma
Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma
Molecular Analysis of Thoracic Malignancies
Tislelizumab Combined With Anlotinib as Second-line Therapy in Thymoma and Thymic Carcinoma
CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors
Survival Nomogram for Patients With Thymic Carcinoma
Molecular Analysis and Treatment Options of Thymic Malignancies
Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors
Ramucirumab and Carbo-Paclitaxel for Untreated Thymic Carcinoma / B3 Thymoma With Carcinoma (RELEVENT)
A Study of KN046 in Patients With Thymic Carcinoma Who Failed Immune Checkpoint Inhibitors
Artificial Intelligence Prediction Tool in Thymic Epithelial Tumors
KN046 (a Humanized PD-L1/CTLA4 Bispecific Single Domain Fc Fusion Protein Antibody) in Subjects With Thymic Carcinoma
Neoadjuvant Treatment For Locally Advanced Thymic Cancer
Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma